CHARACTERIZE CANCER
Methylation signatures identified through Guardant Infinity encoded hormone receptor breast cancer subtypes with high specificity.¹
Apply methylation signature
to stratify patients:
Evaluate patient response to
ARSi based on cancer subtypes¹:
Median overall survival after metastasis¹
CI=Confidence Interval, cfDNA=Cell-Free DNA, IHC=Immunohistochemistry NPA=Negative Percent Agreement, PPA=Positive Percent Agreement
Methylation signatures can improve patient stratification and predict response
to treatment.¹
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma